NicaraguaTuberculosis profile
Population  2017 6.2 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.099 (0.074–0.13) 1.6 (1.2–2.1)
Mortality (HIV+TB only) 0.029 (0.021–0.038) 0.46 (0.33–0.61)
Incidence  (includes HIV+TB) 2.8 (2.2–3.6) 45 (35–57)
Incidence (HIV+TB only) 0.14 (0.088–0.2) 2.2 (1.4–3.1)
Incidence (MDR/RR-TB)** 0.042 (<0.01–0.1) 0.67 (0.13–1.6)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.14 (0.088–0.2) 0.98 (0.61–1.4) 1.1 (0.74–1.5)
Males 0.16 (0.097–0.22) 1.5 (0.95–2.1) 1.7 (1.1–2.3)
Total 0.3 (0.22–0.38) 2.5 (1.8–3.2) 2.8 (2.2–3.6)
TB case notifications, 2017  
Total cases notified 2 328
Total new and relapse 2 255
          - % tested with rapid diagnostics at time of diagnosis 39%
          - % with known HIV status 94%
          - % pulmonary 88%
          - % bacteriologically confirmed among pulmonary 84%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.05 (0.03–0.06)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 103 5%
          - on antiretroviral therapy 81 79%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  38
(10–65)
Estimated % of TB cases with MDR/RR-TB 0.94% (0.09–2.7) 12% (7.3–18)  
% notified tested for rifampicin resistance 67% 84% 1 586
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 38, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 36, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 86% 2 339
Previously treated cases, excluding relapse, registered in 2016 63% 64
HIV-positive TB cases registered in 2016 64% 99
MDR/RR-TB cases started on second-line treatment in 2015 65% 20
XDR-TB cases started on second-line treatment in 2015 100% 1
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 21%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
39% (36–43)
TB financing, 2018  
National TB budget (US$ millions) 9.9
Funding source: 46% domestic, 35% international, 19% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-08-21 Data: www.who.int/tb/data